EVGN Earnings Prediction
The chart below shows how EVGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EVGN sees a +5.42% change in stock price 10 days leading up to the earnings, and a -6.16% change 10 days following the report. On the earnings day itself, the stock moves by -3.54%. This data can give you a slight idea of what to expect for the next quarter's release.
EVGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
EVGN Earnings Analysis
Evogene Ltd Corporation (EVGN.O) Earnings Conference Call
Positive
Earnings Surprise: Evogene Ltd. reported an EPS of $0.06, significantly beating expectations of $-0.72.
Revenue Increase 2024: Total revenues for 2024 reached approximately $8.5 million, up from $5.6 million in 2023, indicating strong growth.
Revenue Increase Overview: In Q4 2024, total revenues were approximately $1.6 million, compared to $0.6 million in Q4 2023, showcasing a substantial increase.
Seed Sales Revenue Growth: Casterra's seed sales contributed to revenue growth, with 250 tons of castor seeds delivered in February 2025 alone, indicating a recovery in production capacity.
AI Drug Discovery Collaboration: Evogene established a collaboration with Google Cloud to develop a GenaRator AI foundation model for drug discovery, reflecting innovation in technology.
R&D Expense Reduction: R&D expenses decreased to approximately $16.6 million in 2024 from $20.8 million in 2023, indicating improved cost management.
Expense Reduction Strategy: The company implemented an expense reduction plan expected to lower costs by approximately 30% starting Q1 2025.
Therapeutic Development Progress: Biomica's clinical study for BMC128 is nearing completion with positive responses from patients, indicating progress in therapeutic development.
Collaboration for Sustainable Weed Control: AgPlenus signed a new collaboration agreement with Bayer for sustainable weed control, enhancing its market position.
Castor Seed Shipment Milestone: Casterra achieved a key milestone with the first shipment of over 100 tons of castor seeds grown in Kenya, expanding its operational footprint.
Negative
Modest Revenue Growth: Total revenues for 2024 were approximately $8.5 million, which, while an increase from $5.6 million in 2023, still reflects a modest growth that may not meet investor expectations for a company in a high-growth sector.
Revenue Shortfall Analysis: In Q4 2024, total revenues were approximately $1.6 million, significantly lower than expected due to a change in the delivery schedule of Casterra’s seeds, which indicates operational inefficiencies.
Production Bottleneck Analysis: Casterra delivered only 76 tons of castor seeds in Q4 2024, while it had already delivered 250 tons in February 2025 alone, highlighting a significant backlog and production bottleneck in the previous quarter.
R&D Expense Decline: R&D expenses for 2024 were approximately $16.6 million, down from $20.8 million in 2023, but this decrease was largely due to the cessation of Canonic’s activities, raising concerns about the sustainability of R&D investment in the future.
Rising Operational Costs: General and administrative expenses increased to approximately $7.4 million in 2024 from $6.1 million in 2023, indicating rising operational costs that could impact profitability.
Operating Loss Reduction: The operating loss for 2024 was approximately $22.2 million, a decrease from $26.5 million in the previous year, but still reflects a significant financial burden on the company.
Net Loss Comparison: The net loss for 2024 was approximately $18.1 million, compared to $26 million in 2023, which, while improved, still raises concerns about the company's long-term financial health and ability to achieve profitability.
EVGN FAQs
How does EVGN typically perform around its earnings report dates?
Is Evogene Ltd (EVGN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EVGN Earning Call Sentiment
Evogene Ltd. (NASDAQ:EVGN) Q4 2024 Earnings Call Transcript
EVGN.O
3.62%Positive
Evogene reported increased revenues and reduced operating losses, with optimistic revenue growth expectations and a strategic focus on partnerships and collaborations. Despite some operational risks and competition, the company's projected cash usage decrease and shareholder return plans are favorable. The Q&A indicates management's confidence in future milestones, although some responses were vague. Overall, the financial improvements and strategic initiatives suggest a positive stock price movement.
